International Society of Nurses in Cancer Care

BIOsim

A train the trainer programme for nurses

Module 4



(Supported by an unrestricted grant from Pfizer)

Patient information

Objectives of the session

At the end of this session the nurse will be able to,

- Understand the information needs of patients
- Understand the importance of engaging local charities
- Survey the patient experience
- Understand the range of patient information
- Appreciate from the patients point of view the implementation process

Information needs

- Definitely needed !
- Honesty and positivity
- Needs to stress positivity of drugs rather than just cheaper
- Note some countries may increase cost as previously not available, all tax payers benefit , reducing wastage
- Engage local charities
- Pharma booklets
- Targeted delivery ie bite size

- PATIENT ENGAGEMENT
  - Patient panel: detailed discussion
  - Ad Hoc discussions with clinic patients
  - Individual letters
  - Through Clinical nurse specialist
  - Sign posting to medicines information

Recognise anxiety

Patients may have a number of concerns about starting or switching to biosimilar treatment.

- 3198 patients surveyed
- Gaps in knowledge about biosimilars included
  - Safety
  - Efficacy
  - Access

Authors concluded

An immediate need exists for patient education about biosimilars and clinical trials to ensure educated and informed decisions are made about biosimilar use.

Jacobs I, Singh E, Sewell KL, Al-Sabbagh A, Shane LG. Patient attitudes and understanding about biosimilars: an international cross-sectional survey. **Patient Prefer. Adherence** 10, 937–948 (2016).

“Patients may have concerns about receiving or switching to biosimilar treatment; they may have questions about how safe the biosimilar is, whether it will be as effective as the originator biologic or if the biosimilar delivery device differs in design and use [16,23,56,57]. The impact of ‘nocebo’ effects, whereby negative expectations of treatment lead to potentially worse outcomes, also needs to be considered by healthcare providers [58,59]. These effects are unrelated to the pharmacology of the drug, in that patients may simply perceive that a drug is less expensive because it is less effective [60]. Enhanced communication by healthcare providers, for example, using ‘soft skills’, can alleviate patient concerns. This strategy has proved successful in patients switching to biosimilars, with fewer patients discontinuing treatment compared with patients transitioning without an enhanced communication strategy [61].

FUTURE ONCOLOGYAHEAD OF PRINTREVIEWopen access
Talking to patients about biosimilarsYelena Y Janjigian, Marco Bissig,Giuseppe Curigliano, Jennifer Coppola & Mark Latymer Published Online:1 Jun 2018https://doi.org/10.2217/fon-2018-0044

- https://www.centerforbiosimilars.com/interviews/stephen-marmaras-the-patient-perspective-on-switching

Communication is key.

- https://www.iapo.org.uk/sites/default/files/files/factsheet6.pdf

How might you engage patients?

International Society of Nurses in Cancer Care

BIOsim

Questions

(Supported by an unrestricted grant from Pfizer)



International Society of Nurses in Cancer Care

BIOsim

A train the trainer programme for nurses

Module 4



(Supported by an unrestricted grant from Pfizer)